154 related articles for article (PubMed ID: 24803183)
1. Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival.
Kanda S; Tsuchiya N; Narita S; Inoue T; Huang M; Chiba S; Akihama S; Saito M; Numakura K; Tsuruta H; Satoh S; Saito S; Ohyama C; Arai Y; Ogawa O; Habuchi T
Int J Cancer; 2015 Jan; 136(1):74-82. PubMed ID: 24803183
[TBL] [Abstract][Full Text] [Related]
2. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy.
Huang CN; Huang SP; Pao JB; Hour TC; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Wu PP; Huang CY; Hsieh CJ; Bao BY
J Intern Med; 2012 May; 271(5):499-509. PubMed ID: 21880074
[TBL] [Abstract][Full Text] [Related]
4. S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.
Shao X; Cai J; Zheng Y; Wang J; Feng J; Huang Y; Shi L; Chen Z; Guo Y; Wang X
Int J Clin Exp Pathol; 2015; 8(5):5309-17. PubMed ID: 26191232
[TBL] [Abstract][Full Text] [Related]
5. CYP19 (aromatase) haplotypes and endometrial cancer risk.
Paynter RA; Hankinson SE; Colditz GA; Kraft P; Hunter DJ; De Vivo I
Int J Cancer; 2005 Aug; 116(2):267-74. PubMed ID: 15800924
[TBL] [Abstract][Full Text] [Related]
6. Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Tang L; Platek ME; Yao S; Till C; Goodman PJ; Tangen CM; Wu Y; Platz EA; Neuhouser ML; Stanczyk FZ; Reichardt JKV; Santella RM; Hsing A; Figg WD; Lippman SM; Thompson IM; Ambrosone CB
Carcinogenesis; 2018 Feb; 39(2):125-133. PubMed ID: 29228205
[TBL] [Abstract][Full Text] [Related]
7. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
8. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
Park IH; Lee YS; Lee KS; Kim SY; Hong SH; Jeong J; Lee H; Ro J; Nam BH
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1263-71. PubMed ID: 21442439
[TBL] [Abstract][Full Text] [Related]
9. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors.
Mononen N; Seppälä EH; Duggal P; Autio V; Ikonen T; Ellonen P; Saharinen J; Saarela J; Vihinen M; Tammela TL; Kallioniemi O; Bailey-Wilson JE; Schleutker J
Cancer Res; 2006 Jan; 66(2):743-7. PubMed ID: 16424004
[TBL] [Abstract][Full Text] [Related]
10. Association of CYP19A1 single-nucleotide polymorphism with digit ratio (2D:4D) in a sample of men and women from Ningxia (China).
Zhanbing M; Jie D; Chunyue B; Hong L; Liang P; Zhenghao H
Early Hum Dev; 2019 May; 132():58-65. PubMed ID: 30986648
[TBL] [Abstract][Full Text] [Related]
11. Association of genetic variations in aromatase gene with serum estrogen and estrogen/testosterone ratio in Chinese elderly men.
Jiang J; Tang NL; Ohlsson C; Eriksson AL; Vandenput L; Chan FW; Ching JK; Kwok A; Orwoll E; Kwok TC; Woo J; Leung PC
Clin Chim Acta; 2010 Jan; 411(1-2):53-8. PubMed ID: 19818337
[TBL] [Abstract][Full Text] [Related]
12. The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men.
Shiota M; Fujimoto N; Tsukahara S; Ushijima M; Takeuchi A; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Eto M
Cancer Chemother Pharmacol; 2019 May; 83(5):933-938. PubMed ID: 30868236
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.
Haiman CA; Dossus L; Setiawan VW; Stram DO; Dunning AM; Thomas G; Thun MJ; Albanes D; Altshuler D; Ardanaz E; Boeing H; Buring J; Burtt N; Calle EE; Chanock S; Clavel-Chapelon F; Colditz GA; Cox DG; Feigelson HS; Hankinson SE; Hayes RB; Henderson BE; Hirschhorn JN; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Le Marchand L; Lenner P; Lund E; Panico S; Peeters PH; Pike MC; Riboli E; Tjonneland A; Travis R; Trichopoulos D; Wacholder S; Ziegler RG
Cancer Res; 2007 Mar; 67(5):1893-7. PubMed ID: 17325027
[TBL] [Abstract][Full Text] [Related]
14. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M
J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655
[TBL] [Abstract][Full Text] [Related]
15. Alcohol-related breast cancer in postmenopausal women - effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial.
Kopp TI; Jensen DM; Ravn-Haren G; Cohen A; Sommer HM; Dragsted LO; Tjonneland A; Hougaard DM; Vogel U
BMC Cancer; 2016 Apr; 16():283. PubMed ID: 27102200
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.
Long JR; Kataoka N; Shu XO; Wen W; Gao YT; Cai Q; Zheng W
Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2115-22. PubMed ID: 17119036
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients.
Teixeira AL; Ribeiro R; Cardoso D; Pinto D; Lobo F; Fraga A; Pina F; Calais-da-Silva F; Medeiros R
Clin Cancer Res; 2008 Jun; 14(11):3367-71. PubMed ID: 18519765
[TBL] [Abstract][Full Text] [Related]
18. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
19. Haplotype structures and functional polymorphic variants of the drug target enzyme aromatase (CYP19A1) in South Indian population.
Umamaheswaran G; Dkhar SA; Kalaivani S; Anjana R; Revathy M; Jaharamma M; Shree KM; Kadambari D; Adithan C
Med Oncol; 2013; 30(3):665. PubMed ID: 23893151
[TBL] [Abstract][Full Text] [Related]
20. CYP19A1 gene polymorphisms and risk of lung cancer.
Zhang J; Yin Y; Niu XM; Liu Y; Garfield D; Chen SF; Wang R; Wang L; Chen HQ
J Int Med Res; 2013 Jun; 41(3):735-42. PubMed ID: 23669293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
